11C Choline PET Guided Salvage Radiotherapy with Volumetric Modulation Arc Therapy and Hypofractionation for Recurrent Prostate Cancer after HIFU Failure: Preliminary Results of Tolerability and Acute Toxicity

Abstract

The purpose of this work was to evaluate tolerance, feasibility and acute toxicity in patients undergoing salvage radiotherapy after high-intensity focused ultrasound (HIFU) failure. From 2005 to 2011 a total of 15 patients were treated with HIFU as primary radical treatment. Between July 2011 and February 2013, all 15 patients presented biochemical relapse after HIFU and 11C choline PET documenting intrapostatic-only failure. Salvage EBRT was performed with moderate hypofractionation schedule in 28 fractions with volumetric modulation arc therapy (VMAT). Genito-urinary (GU) and rectal and bowel toxicity were scored by common terminology criteria for adverse events version 4 (CTCAE V.4) scale. Biochemical response was assessed by ASTRO Phoenix criteria. Median age of patients was 67 years (range: 53–85). The median Gleason score was 7 (range: 6–9). The median prostate specific antigen (PSA) at the time of biochemical relapse after HIFU was 5.2 ng/mL (range: 2–64.2). Seven of the 15 patients received androgen deprivation therapy (ADT) started after HIFU failure, interrupted before 11C choline PET and radiotherapy. Median prescribed dose was 71.4 Gy (range: 71.4–74.2 Gy) in 28 fractions. No radiation related major upper gastrointestinal (GI), rectal and GU toxicity were experienced. GU, acute grade 1 and grade 2 toxicities were recorded in 7/15 and 4/15 respectively; bowel acute grade 1 and grade 2 toxicities in 4/15 and 1/15; rectal acute grade 1 and grade 2 toxicities in 3/15 and 2/15 respectively. No grade 3 or greater acute or late toxicities occurred. Biochemical control was assessed in 12/15 (80%) patients. With a median follow up of 12 months, three out of 15 patients, with biochemical relapse, showed lymph-nodal recurrence. Our early clinical results and biochemical data confirm the feasibility and show a good tolerance of the 11C choline PET guided salvage radiation therapy after HIFU failure. The findings of low acute toxicity is encouraging, but longer follow-up is needed to assess late toxicity and definitive outcomes.

Keywords

PET HIFU Salvage radiotherapy Prostate

References

Rebillard

Soulié

Chartier-Kastler

Davin

Mignard

& Coulange

. High-intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology. BJU Int 101, 1205–1213 (2008). DOI: 10.1111/j.1464-410X.2008.07504.

Gelet

Chapelon

Bouvier

Rouvière

Lyonnet

& Dubernard

. Transrectal high intensity focused ultrasound for the treatment of localized prostate cancer: factors influencing the outcome. Eur Urol 40, 124–129 (2001).

Murat

Poissonnier

Rabilloud

Belot

Bouvier

Rouviere

Chapelon

& Gelet

. Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer. Eur Urol 55, 640–647 (2009). DOI: 10.1016/j.eururo.2008.04.091.

Gelet

Chapelon

Poissonnier

Bouvier

Rouvière

Curiel

Janier

& Vallancien

. Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography. Urology 63, 625–629 (2004).

Murat

Poissonnier

Rabilloud

Belot

Bouvier

Rouviere

Chapelon

& Gelet

Otto

. Volumetric modulated arc therapy: IMRT in a single gantry arc. Med Phys 35, 310–317 (2008).

Arcangeli

Scorsetti

& Alongi

. Will SBRT replace conventional radiotherapy in patients with low-intermediate risk prostate cancer? A review. Crit Rev Oncol Hematol 84, 101–108 (2012). DOI: 10.1016/j.critrevonc.

Alongi

& Scorsetti

. Hypofractionation in current clinical practice: a flash forward to the near future of radiation oncology? Tumori 98, 395–397 (2012). DOI: 10.1700/1125.12412.

Pasticier

Chapet

Badet

. Salvage radiotherapy after high intensity focused ultrasound for localized prostate cancer: early clinical results. Urology 72, 1305–1309 (2008). DOI: 10.1016/j.urology.2008.02.064.

10.

Riviere

Bernhard

Robert

Wallerand

Deti

Maurice-Tison

Ardiet

Maire

Richaud

Ferriere

Ballanger

Gelet

& Pasticier

. Salvage radiotherapy after high-intensity focussed ultrasound for recurrent localised prostate cancer. Eur Urol 58, 567–573 (2010). DOI: 10.1016/j.eururo.2010.06.003.

11.

Ripert

Bayoud

Messaoudi

Ménard

Azémar

Duval

Nguyen

& Staerman

. Salvage radiotherapy after high-intensity focused ultrasound treatment for localized prostate cancer: feasibility, tolerance and efficacy. Can Urol Assoc J 6, 179–83 (2012). DOI: 10.5489/cuaj.10137.

12.

Munoz

Guarneri

Botticella

Gabriele

Moretto

Panaia

Ruggieri

D'Urso

Muto

Filippi

Ragona

& Ricardi

. Salvage External Beam Radiotherapy for Recurrent Prostate Adenocarcinoma after High-Intensity Focused Ultrasound as Primary Treatment. Urol Int (2013) (in press).

13.

Alongi

Fogliata

Navarria

Tozzi

Mancosu

Lobefalo

Reggiori

Clivio

Cozzi

& Scorsetti

. Moderate hypofractionation and simultaneous integrated boost with volumetric modulated arc therapy (RapidArc) for prostate cancer. Report of feasibility and acute toxicity. Strahlenther Onkol 188, 990–996 (2012). DOI: 10.1007/s00066-012-0171-7.

14.

Di Muzio

Fiorino

Cozzarini

Alongi

Broggi

Mangili

Guazzoni

Valdagni

Calandrino

& Fazio

. Phase I-II study of hypofractionated simultaneous integrated boost with tomotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 1, 392–398 (2009). DOI: 10.1016/j.ijrobp.2008.08.038.

15.

Alongi

Fiorino

Cozzarini

Broggi

Perna

Cattaneo

Calandrino

& Di Muzio

. IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy. Radiother Oncol 93, 207–212 (2009). DOI: 10.1016/j.radonc.2009.08.042.

16.

Warmuth

Johansson

& Mad

. Review Systematic review of the efficacy and safety of high-intensity focused ultrasound for the primary and salvage treatment of prostate cancer. Eur Urol 58, 803–815 (2010). DOI: 10.1016/j.eururo.2010.09.009.

17.

Blana

Brown

Chaussy

Conti

Eastham

Ganzer

Murat

Pasticier

Rebillard

Rewcastle

Robertson

Thuroff

& Ward

. High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure. BJU Int 104, 1058–1062 (2009). DOI: 10.1111/j.1464-410X.2009. 08518.x.

18.

Krause

Souvatzoglou

& Treiber

. Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates. Urol Oncol (2011) (in press).

19.

Martino

Scattoni

Galosi

. Role of imaging and biopsy to assess local recurrence after definitive treatment for prostate carcinoma (surgery, radiotherapy, cryotherapy, HIFU). Word J Urol 29, 595–605 (2011). DOI: 10.1007/s00345-011-0687-y.

20.

Breeuwsma

Pruim

van den Bergh

Detection of local, regional, and distant recurrence in patients with PSA relapse after external-beam radiotherapy using (11C)-choline positron emission tomography. Int J Radiat Oncol Biol Phys 77, 160–164 (2010). DOI: 10.1016/j.ijrobp.2009.04.090.

21.

Rinnab

Mottaghy

Blumstein

. Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int 100, 786–793 (2007).

22.

Souvatzoglou

Krause

Pürschel

Thamm

Schuster

Buck

Zimmermann

Molls

Schwaiger

& Geinitz

. Influence of (11)C-choline PET/CT on the treatment planning for savage radiation therapy in patients with biochemical recurrence of prostate cancer. Radiother Oncol 99, 193–200 (2011). DOI: 10.1016/j.radonc.2011.05.005.

23.

Würschmidt

Petersen

Wahl

Dahle

& Kretschmer

. [18F] fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes. Radiat Oncol 1(6), 44 (2011). DOI: 10.1186/1748-717X-6-44.

24.

Alongi

Schipani

Gajate

Rosso

Cozzarini

Fiorino

Alongi

Picchio

Gianolli

Messa

& Di Muzio

. [11C]choline-PET-guided helical tomotherapy and estramustine in a patient with pelvic-recurrent prostate cancer: local control and toxicity profile after 24 months. Tumori 96, 613–617 (2010).

25.

Rouvière

Vitry

& Lyonnet

. Imaging of prostate cancer local recurrences: why and how? Eur Radiol 20, 1254–66 (2010).